Skip to main content

Home/ Dr. Goodyear/ Group items tagged 7

Rss Feed Group items tagged

Nathan Goodyear

Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloprotein... - 0 views

  •  
    Triptolide, a component of thunder god vine (Tripterygium wilfordii) found to counter ovarian cancer through decreased matrix metalloproteinase 7 and 19 as well as increasing E-cadherin. This effect reduces invasion and spread of cancer.
wheelchairindia9

S-Ergo 105 - 0 views

  •  
    Ergonomic chairs are designed to confirm to a person's physical dimensions, allowing them to sit naturally and comfortably for long periods of time, while reducing the risk of pressure ulcers. Karma Wheelchair KM 7501: Karma Healthcare KM 7501 Pediatric Wheelchair is a manual wheelchair for children. It's ergonomically antelope horn-shaped handle makes it easy to steer and push the chair, and vertical footrest allow legs to be placed in the correct position. One-piece footplate increases stability. The wheelchair has a great look with a bright color and modern style. Karma Healthcare Wheelchair KM 7501 Features: Karma Healthcare Wheelchair KM-7501 Paediatric Wheelchair offers here-we-go handle Caring footrest Seat width: 11" or 13.5" Ultra lightweight and compact Outward extended front wheels 6" solid caster and 14" solid rear wheel Maximum user weight: 60Kg One Year Warranty Karma Wheelchair KM 7501 Measurements: Width 11" And 13.5" Front/Rear Wheels 6" to 14" 6" to 14" Seat Width 28cm 34cm Seat Depth 30cm 30cm Overall Width 45cm 51cm Overall Collapsed Width 34cm 34cm Armrest Height 18cm 18cm Overall Length 70W 70W Seat Height 39cm 39cm Backrest Height 36cm 36cm Overall Height 102cm 102cm Weight 9.3kg 9.3kg Ergo Wheelchair features an ergonomic "S" shaped seat that provides the perfect shape to fit the human body to relieve pressure, increase stabilization, weight distribution and lower the risk of pressure sores and scoliosis. Karma S Ergo 105 Wheelchair Karma S Ergo 105 Wheelchair Features: High strength, weighs only 12.2 kg. (w/ footrests) ¼" thick removable Aegis Anti-Bacterial Upholstery, machine washable / dryable "Tube-in Center" footplate, assures better side leg support Fixed Footrests Pouch for carrying small items attached to upholstery behind backrest 7"x1" Polyurethane front caster 24' Rear polyurethane, high profile, flat free wheels S-Style Ergonomic Seat Folding backrest/ folding seat for tra
wheelchairindia9

Karma S-Ergo 105 Manual Wheelchair - 0 views

  •  
    Ergonomic chairs are designed to confirm to a person's physical dimensions, allowing them to sit naturally and comfortably for long periods of time, while reducing the risk of pressure ulcers. Ergonomic system (Intelligent s-shaped ergonomic seating) provides efficient pressure relief by spreading weight over a greater area, at the same time provides stabilization and reduced sliding. With their lightweight frames and seats designed to reduce or prevent pressure points, ergonomic wheelchairs provide a comfortable option for mobility impaired users who have the upper body strength to propel themselves, or a caregiver strong enough to do so. Karma Ergo Lite 2501 Wheelchair: The extremely lightweight Ergo Lite 2501 Transport Wheelchair weighs only 8.16 kg. and features an ergonomically-designed seat and backrest, making it one of the most comfortable transport chairs on the market. The folding seat and backrest make the S-Ergo ideal for storage or travel, and the built in AEGIS anti-bacterial cushion provides added comfort and support. Despite its light weight, the S-Ergo features a 115 kg. weight capacity along with large, 14" flat-free polyurethane rear tires. Karma Ergo Lite 2501 Wheelchair Features: Lightest transporter on the market! Patented S-Style Ergonomic Seat Frame 6061 T-6 Aircraft-grade Aluminum Only 18 lb . (w/ footrests) Built in Silver Aegis Anti-bacterial Cushion Fixed Armrests w/Concaved Armpads Pocket Behind Backrest & Small Carry Pouch on Each Armrest 6" x 1" Polyurethane Front Casters 16" x 17" or 18" x 17" Seat Width S-Style Ergonomic Seat 14" Rear Polyurethane, High Tread, Flat Free Wheels 3-Stage handle brake: allows light to firm grip for lock Folding Backrest/ Folding Seat for Transporting in Vehicle or Travel Fixed Footrests w/ Extra Wide Footplates Frame Color: Pearl Silver Weight Capacity of 100 kg Ergonomic Transporter w/ handle brakes Karma Ergo Lite 2501 Wheelchair Measurements: Seat Width 16 inch., 18
star yu

La Creatinina 4.7 en PKD Significa Qué y Cómo Bajarla - 0 views

  •  
    Mi padre ha sido diagnosticada de la enfermedad renal poliquística ,y el doctor nos dijo que su nivel de creatinina ya hasta 4,7.¿Puede decirme qué significa la creatinina 4.7 y cómo bajarla ? ¿Qué significa la creatinina 4.7 ? La creatinina 4,7 en PKD significa: 1.Sus nefronas han sido dañados más de 70%.
star yu

El Nivel de Creatinina es 4.7 en Insuficiencia Renal Cómo Tratarla - 0 views

  •  
    Si el nivel de creatinina hasta 4.7 en insuficiencia renal ,cómo tratarla ? Sabes, el nivel de creatinina 4.7 es más mayor que el nivel normal, ahora el nivel de creatinina pertenece a la etapa 3 de la enfermedad renal y cerca a la etapa 4.Así que para los pacientes con tan alto nivel de creatinina deben tomar el tratamiento adecuado a tiempo.
star yu

Creatinine 1.7 in Chronic Kidney Disease Is It Possible to Reverse It - 0 views

  •  
    Creatinine 1.7 in Chronic kidney disease is it possible to reverse it ? As we all know there are many factors can induce creatinine level goes high, but no matter what causes, creatinine 1.7 can be reversed with timely treatment.
wheelchairindia9

Karman S-Ergo 115 - 0 views

  •  
    Ergonomic wheelchairs have been tested and proven to be effective for relieving pressure throughout the body; this is confirmed by pressure chart mapping. Feeling comfortable on a wheelchair is something every user demands out of their new wheelchair, the ergonomic cushion that is included with the ergonomic series provides a level of comfort that is unparalleled. Ergonomic Transport Wheelchair provides the perfect shape to fit the human body to relieve pressure, increase stabilization, weight distribution and lower the risk of pressure sores and scoliosis. Lightweight Ergonomic Wheelchair features wide arm pads for extra support, folding back rest, detachable swing-away footrests, and a Tube-in Center foot-plate that provides extra support for the leg muscles. This wheelchair can hold up to daily use and is excellent for traveling. Ergonomic features flip-back armrest and swing away footrests. A lightweight frame that is 25 lbs. without footrests and a folding backrest allows easy travel or storage. The chair comes equipped with a padded anti-bacterial upholstery that is comfortable and washable. Karma Ergo Lite 2501 Wheelchair: The extremely lightweight Ergo Lite 2501 Transport Wheelchair weighs only 8.16 kg. and features an ergonomically-designed seat and backrest, making it one of the most comfortable transport chairs on the market. The folding seat and backrest make the S-Ergo ideal for storage or travel, and the built in AEGIS anti-bacterial cushion provides added comfort and support. Despite its light weight, the S-Ergo features a 115 kg. weight capacity along with large, 14" flat-free polyurethane rear tires. Karma Ergo Lite 2501 Wheelchair Features: Lightest transporter on the market! Patented S-Style Ergonomic Seat Frame 6061 T-6 Aircraft-grade Aluminum Only 18 lb . (w/ footrests) Built in Silver Aegis Anti-bacterial Cushion Fixed Armrests w/Concaved Armpads Pocket Behind Backrest & Small Carry Pouch on Each Armrest 6" x 1" Polyurethane
wheelchairindia9

Soma SM 100.3 - 0 views

  •  
    Soma SM 100.3 The SM-100.3 is an aluminum alloy standard wheelchair that is economic, solid, and durable. Soma SM 100.3 Wheelchair Features: Elliptical frame The unique and stylish elliptical frame ensures that the chair is both rigid and robust. Integrated seating system For intensive wheelchair users, we provide seating system that can be free from hammock effect. The innovative and durable seating system makes it easy for you to detach seat upholstery for cleaning purpose. Secure non-slip footplate A non-slip and ergonomic footplate provides you with a stable and comfortable base for placing feet. Energy-saving tipping lever The ergonomic design allows caregivers to operate the lever without much effort so the casters can overcome obstacles such as thresholds and curbs. Soma SM 100.3 Wheelchair Measurements: Seat Width(cm):43 Seat Depth(cm):42 Caster Size(inch):7 Rear Wheel Size(Inch/QR) 16F/22F
Nathan Goodyear

Insulin-induced enhancement of MCF-7 breast cancer cell response to 5-fluorou... - 0 views

  •  
    Study finds that insulin potentiates chemo cytotoxic therapy in MCF-7 breast cancer cell lines.
Nathan Goodyear

Genetic Determinants of Serum Testosterone Concentrations in Men - 0 views

  • mean serum testosterone concentrations were found to be lower in men with GG than in those with TT genotype for rs12150660
  • men with the CT genotype for rs6258 had lower serum testosterone concentrations than those with CC genotype.
  • The two autosomal SNPs identified by GWAS had a significant influence on the risk of having low serum testosterone (serum testosterone <300 ng/dl) in both the discovery and the replication cohorts with a combined odds ratio (OR) per minor allele of 0.72 (95% CI, 0.65 – 0.79) and 2.7 (95% CI, 2.1 – 3.5) for rs12150660 and rs6258, respectively
  • ...3 more annotations...
  • The risk of having low serum testosterone concentrations increased by the number of risk alleles with an OR of 1.62 (95% CI, 1.41 – 1.86) for each risk allele (Figure S4). Low serum testosterone concentrations were 6.5-times more prevalent in men with ≥3 risk alleles (30.1% prevalence of low serum testosterone) compared to men without any risk allele (4.6% prevalence of low serum testosterone;
  • SNP rs5934505 was associated with serum testosterone without SHBG-adjustment (combined p-value of 1.7×10−9) and with free testosterone (combined p-value of 6.7×10−15), but not with SHBG
  • The mean serum testosterone and calculated free testosterone but not SHBG concentrations were lower in men with T genotype than in those with C genotype for rs5934505
  •  
    Genetic SNP rs5934505 associated with lower total Testosterone and lower calculated free Testosterone.  No effects on SHBG.
Nathan Goodyear

In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epitheli... - 0 views

  • we functionally validated a potent EOC oncogene, KPNB1, and showed its clinical relevance to human EOC
  • a well-established antiparasitic drug, ivermectin, has antitumor effects on EOC through its inhibition of KPNB1
  • EOC has high intertumor and intratumor heterogeneity at the molecular and epigenetic levels
  • ...22 more annotations...
  • the mortality rate of EOC has not been significantly changed for several decades
  • Sequencing revealed that almost all tumors (96%) had mutations in TP53, which serves as a major driver of this cancer
  • Low-prevalence but statistically significant mutations in nine other genes including NF1, BRCA1, BRCA2, RB1, and CDK12 were also identified, but the majority of genes were mutated at low frequency, making it difficult to distinguish between driver and passenger mutations
  • KPNB1 inhibition via any of three KPNB1 siRNAs or importazole treatment induced apoptosis in human EOC cell lines (Fig. 3 A–F and Fig. S4), and was accompanied by an increase in the expression levels of the proapoptotic proteins BAX and cleaved caspase-3
  • Stable overexpression of KPNB1 in SKOV3 and OVCAR3 (Fig. S6) significantly accelerated cell proliferation/survival (Fig. 5 A–C), confirming that KPNB1 functions as an oncogene in EOC
  • KPNB1 overexpression significantly decreased caspase-3/7 activity (Fig. 5D), in addition to the expression levels of cleaved caspase-3 and BAX proteins (Fig. 5E). KPNB1 overexpression also decreased p21 and p27 protein levels (Fig. 5E), as opposed to their increase by KPNB1 inhibition
  • KPNB1 functions as an antiapoptotic and proproliferative oncogene in EOC.
  • Patients with higher expression levels of KPNB1 showed earlier recurrence and worse prognosis than those with lower expression levels of KPNB1
  • KPNB1 acts as an oncogene in human EOC and represents a promising therapeutic target.
  • ivermectin treatment suppressed cell proliferation/viability in a dose-dependent manner (Fig. 7A), indicating that it exerts an antitumor effect on EOC
  • ivermectin also induced apoptosis
  • ivermectin increased the expression levels of BAX, and cleaved PARP, as well as p21 and p27
  • KPNB1 inhibition is responsible for the antitumor effect of ivermectin
  • we found that ivermectin synergistically reduced cell proliferation/viability in combination with paclitaxel in human EOC cells
  • Single treatment of ivermectin or paclitaxel reduced tumor growth in nude mice, but, notably, combination treatment of ivermectin and paclitaxel almost completely suppressed tumor growth
  • ERBB2, is amplified and overexpressed in many cancers, including breast (31), ovary (31), colon (32), bladder (33), non-small-cell lung (34), and gastric cancer (35), and is a poor prognostic factor in certain cancer types
  • KPNB1 was the second-highest-ranked gene identified in our screen
  • Increased KPNB1 protein levels have been reported in several cancers, including cervical cancer (42), hepatocellular carcinoma (43), and glioma (44), suggesting KPNB1’s oncogenic potential in these tumor types
  • our findings suggest that KPNB1 might serve as a master regulator of cell cycle by regulating several cell cycle-related proteins, including p21, p27, and APC/C family members
  • higher and/or more-frequent doses of ivermectin than currently approved for humans are well tolerated in humans
  • none of the mice in this study treated with the effective dosage of ivermectin for in vivo anticancer therapy showed severe adverse event
  • we found that the combination of ivermectin and paclitaxel produces a stronger antitumor effect on EOC cell lines than either drug alone
  •  
    Ivermectin found to be pro-apoptotic for the epithelial ovarian cancer oncogene, KPNB1 in in Vivo study.  This effective anti-parasitic drug inhibits the KPNB1 oncogene.
Nathan Goodyear

Plasma Membrane Receptors for the Cancer-Regulating Progesterone Metabolites,... - 0 views

  •  
    The receptor for the progesterone 5alpha pregnane, 5alpha-P, is unregulated in breast cancer cell line MCF-7.  Estradiol increases the receptor expression.  Not only is there an enzymatic effect in these progesterone pathways, but the receptor is equally unregulated.
Nathan Goodyear

Trastuzumab and Interleukin-2 in HER2-positive Metastatic Breast Cancer | Clinical Canc... - 0 views

  •  
    Herceptin and IL-2 increase NK cell expansion when used in conjunction.  The IL-2 was the low dose protocol for 7 weeks.
Nathan Goodyear

Availability of evidence of benefits on overall survival and quality of life of cancer ... - 0 views

  • Although the goal of cancer treatment is to improve the quantity and quality of life,123 clinical trials designed to gain regulatory approval for new drugs often evaluate indirect or “surrogate” measures of drug efficacy. These endpoints show that an agent has biological activity, but they are not reliable surrogates for improved survival4567891011 or quality of life46111213
  • two recent systematic reviews suggest that the strength of association between surrogates in cancer clinical trials and life extension is generally low
  • Available data from the US show that only a small proportion of cancer treatments approved by the US Food and Drug Administration (FDA) unequivocally show benefits on survival or quality of life.30
  • ...16 more annotations...
  • We sought to systematically evaluate the evidence base for all new drugs and new indications for the treatment of solid tumours and haematological malignancies approved by the EMA in the five year period 2009-13
  • Three investigators (AP, EP, and EG) independently extracted data on and descriptively analysed the following trial features: characteristics of the participant population, study design (randomisation, crossover from experimental to control group, and blinding of investigators and participants), experimental and control groups, enrolment, primary and secondary endpoints, magnitude of benefit on survival and quality of life, and narrative interpretation of the findings
  • Only 18 of the 68 (26%) were supported by a pivotal study powered to evaluate overall survival as the primary outcome
  • From 2009 to 2013, the EMA approved use of 48 oncology drugs
  • Seventeen drugs were approved for treatment of haematological malignancies and 51 for treatment of solid tumours
  • Overall, 72 clinical trials supported the approval of 68 novel drug uses
  • Our scoring was limited to drugs for solid tumours
  • Among 68 cancer drug indications approved by the EMA in the period 2009-13, and with a median of 5.4 years’ follow-up, only 35 (51%) were associated with a significant improvement in survival (26/35) or quality of life (9/35) over existing treatment options, placebo, or as add on treatment
  • Only two of the 26 drugs shown to extend life also showed benefits on quality of life
  • 33 (49%) had not shown any improvement on survival or quality of life
  • This systematic evaluation of oncology drug approvals by the EMA in 2009-13 shows that most of the drugs (39/68, 57%) entered the market without evidence of improved survival or quality of life
  • At a minimum 3.3 years after market entry, there was still no conclusive evidence that 33 of these 39 cancer drugs either extended or improved life
  • What are potential reasons for the paucity of drug approvals with demonstrable survival advantages over existing treatments?
  • Firstly, only 18 (26%) indications for use in our cohort were supported by trials in which extension of life was the primary outcome
  • None of the pivotal studies supporting oncology drug approvals from 2009 to 2013 included quality of life as a primary outcome measure
  • Most new oncology drugs authorised by the EMA in 2009-13 came onto the market without clear evidence that they improved the quality or quantity of patients’ lives
  •  
    New study from European Medicines Agency questions alot of the new cancer drugs brought to the market 2009-2013.  57% of the new drugs (39/68) were brought to the market without evidence of improved survival or quality of life.
Nathan Goodyear

Imbalance in Sex Hormone Levels Exacerbates Diabetic Renal Disease - 0 views

  •  
    Diabetes associated with low serum testosterone.  This study points to a 4.7 fold decrease.  This is accompanied by a 2.9 fold increase in estradiol.  Castration worsened this imbalance by decreasing the testosterone level further.  Likely the low T and increased aromatase activity aid in the development of diabetic renal disease. Numerous studies have shown that testosterone therapy improves glucose homeostasis.
Nathan Goodyear

1506 TESTOSTERONE REPLACEMENT THERAPY AND CANCER RISK - 0 views

  •  
    Testosterone therapy found to not increase cancer risk in men.  This chart review, looked at 722 men over an average of 8.7 years to assess risk of cancer associated with testosterone therapy. This study was presented at the AUA in 2013.
Nathan Goodyear

Cancer as a metabolic disease - 0 views

  •  
    Dr. Seyfried provides a different perspective on cancer as a metabolic disease and not as a "genetic" disease as is the current dogma. Dr. Seyfried is well published on this topic and presents valid points to show that a ketogenic diet with intermittent fasting is anti-cancer.
Nathan Goodyear

Beta Glucan: Health Benefits in Obesity and Metabolic Syndrome - 0 views

  • beta glucan (β-glucan), which is a dietary fiber readily found in oat and barley bran
  • Among cereals, the highest content (g per 100 g dry weight) of β-glucan has been reported for barley: 2–20 g (65% is water-soluble fraction) and for oats: 3–8 g (82% is water-soluble fraction). Other cereals also contain β-glucan but in much lower amounts: sorghum 1.1–6.2 g, rye 1.3–2.7 g, maize 0.8–1.7 g, triticale 0.3–1.2 g, wheat 0.5–1.0 g, durum wheat 0.5-0.6 g, and rice 0.13 g
  • Other sources of β-glucan include some types of seaweed [17] and various species of mushrooms such as Reishi, Shiitake, and Maitake [18].
  • ...5 more annotations...
  • Distinction between soluble and insoluble dietary fibers is based on the solubility characteristics of dietary fiber in hot aqueous buffer solutions
  • Insoluble fibers primarily consist of cellulose and some hemicelluloses, resistant starch, and chitin while soluble fibers include pectins, β-glucans, galactomannan gums, mucilages, and some hemicelluloses
  • insoluble fibers increase fecal bulk and the excretion of bile acids and decrease intestinal transit time
  • Soluble fibers increase total transit time by delaying gastric emptying and also slow glucose absorption
  • only soluble viscous fibers delay gastric emptying time and slow glucose absorption while nonviscous soluble fibers primarily act as a substrate for microbial fermentation in the colon
  •  
    good review on Beta glucan.
Nathan Goodyear

The Ketogenic Diet and Sport: A Possible Marriage? : Exercise and Sport Sciences Reviews - 0 views

  • It is important to note that, although the blood level of glucose drops, it still remains at a physiological level (23), which is maintained through gluconeogenesis involving glucogenic amino acids and also glycerol released from triglycerides
  • “physiological ketosis” where KB levels may rise to 7 to 8 mmol L-1 (but without any pH change). In “pathological diabetic ketoacidosis,” on the other hand, ketonemia can exceed 20 mmol L-1 and also cause lowering of blood pH
  • in the initial phase of KD, about 16% of glucose comes from glycerol (released from triglyceride hydrolysis) and the bulk (60–65 g) from proteins via gluconeogenesis (proteins may be of either dietary or endogenous origin
  • ...5 more annotations...
  • the protein supply consumed during a KD “preserves,” as demonstrated, lean body mass
  • The importance of glycerol as a glucose source increases progressively during ketosis; in fact, glycerol passes from supplying 16% of total glucose to an average of 60% after many days (>7 d) of complete fasting (from 38% in lean individual to 79% in the obese).
  • The possible reasons for the effectiveness of KD for weight loss may be listed as follows, in order of evidence, strongest first: Figure 3Image Tools 1. Appetite reduction: protein satiety, effects on appetite-related hormones such as ghrelin, and possibly a sort of direct appetite-blocking effect of KB 2. Reduced lipogenesis and increased fat oxidation 3. A reduction in respiratory quotient may indicate a greater metabolic efficiency in fat oxidation 4. A thermic effect of proteins and increased energy usage by gluconeogenesis
  • all data regarding biochemical and molecular mechanisms suggest that it is very difficult to increase muscle mass during a KD; use of which really should be limited to the few days immediately before competition in bodybuilding.
  • a long-term KD can interfere with some muscle hypertrophy mechanisms and this could be counterproductive if the aim of the athlete is to gain muscle mass
  •  
    Great read on the ketogenic  and its application to sports/training...
Nathan Goodyear

Reproductive toxicologic evaluations of Bulbine natalensis Baker stem extract in albino... - 0 views

  •  
    Bulbine natalensis Baker stem extract found to increase LH and Testosterone in wistar rats in 7 days at doses of 25 to 50 mg/kg; this effect was not found at 100 mg/kg.  The result was an increase in testes size, rate of mating, libido, and fertility.
‹ Previous 21 - 40 of 439 Next › Last »
Showing 20 items per page